Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company's Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial executive with decades of experience working with and advising private and public life sciences companies. Shaun Chilton, Chairman of the Board of Avacta, commented: "Avacta is at a pivotal time in its e

Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that James Sandy has been appointed as Chief Development Officer, effective today. Mr. Sandy will lead the clinical development and advancement of F-star's pipeline. "We are delighted to welcome James to F-star," said Eliot Forster, CEO of F-star Therapeutics, Inc. "James brings an unparalleled depth of experience in drug development in oncology and a strong track record of enhancing and accelerating clin

DURHAM, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc., a leader in the field of developing inhaled therapies to treat severe respiratory and chronic diseases, today announced the appointment of Darlene Deptula–Hicks, Chief Financial Officer of F-star Therapeutics, Inc., to its board of directors and chair of the audit committee. "I am delighted to welcome Darlene to our board of directors," said Steve Thornton, chief executive officer of Aerami. "She is a seasoned financial executive who brings decades of experience in business development and corporate finance having worked with both private and public life science companies. We look forward to her strategic operation

Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of Darlene Deptula-Hicks as a member of the company's Board of Directors. Ms. Deptula-Hicks is a highly regarded financial executive with decades of experience working with and advising private and public life sciences companies. "We are excited to welcome Darlene to our Board of Directors at this important time in our company," said David de Graaf, Chief Executive Officer of Abcuro. "Darlene brings an impressive, thirty-year track record working with both publicly traded and venture-backed life

invoX Pharma Limited ("invoX"), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited ("Sino Biopharm") (HKEX 1177 HK) with an advancing pipeline of innovative products, today announces that it has successfully completed the acquisition of F-star Therapeutics, Inc. ("F-star") (NASDAQ:FSTX), a clinical-stage biopharmaceutical company pioneering bispecific antibodies in immunotherapy, for an aggregate cash consideration of approximately $161 million (or $7.12 per share). F-star is currently executing Phase 2 trials in Europe and the U.S. in patients with PD-1 acquired resistant head and neck cancer, and in checkpoint inhibitor-naïve patients with non-small cell lung cancer (

Previously announced agreement for F-star Therapeutics to be acquired by invoX Pharma; transaction expected to close in the second half of 2022 License Agreement with Takeda to Develop and Commercialize a Novel Next-Generation Immuno-Oncology Bispecific Antibody TherapeuticFS118 Cleared the Futility Hurdle for the Initial Stage of the Head and Neck Acquired Resistance Cancer Trial Initiation of Combination Dosing with FS120 and KEYTRUDA® in Patients with Advanced Cancers under Supply Agreement with MSD Company Will Not be Hosting Q2 2022 Earnings Conference Call Due to the Pending Transaction with invoX Pharma CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE)

Four Clinical Readouts Anticipated Throughout 2022 Mechanistic Data on FS118 Demonstrating Shedding Mechanism and LAG-3 Reduction Presented at the 2022 American Association for Cancer Research (AACR) Annual MeetingCompany To Host Conference Call Today at 9:00 a.m. EDT CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX) ("F-star" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to transform the lives of patients with cancer, today announced first quarter 2022 financial results and provided a corporate update. "This year is one of the most important yea

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that the Company will hold a conference call and webcast on May 10th, 2022, at 9:00 a.m. EST to review first quarter 2022 financial results and provide a corporate update. To access the call, participants may join via a live webcast on the Investors & News section of the F-star Therapeutics website, under Events and Presentations. To join by phone, participants may dial the following numbers at least 10 minut

Multiple Clinical Program Updates Expected in 2022 Continued Expansion of Leading Bispecific Antibody IP Estate Two New Significant Partnerships with Janssen and AstraZeneca Company to Host Conference Call Today at 9 a.m. EDT CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced full-year 2021 financial results and will provide a corporate update. "Bispecifics have come of age, and F-star is exceptionally well positioned in this field with our unique tetra

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that the Company will hold a conference call and webcast on March 14, 2022, at 9:00 a.m. EST to review fourth quarter and full-year 2021 financial results and provide a corporate update. To access the call, participants may join via a live webcast on the Investors and News section of the F-star Therapeutics website, under Events and Presentations. To join by phone, participants may dial the following number

Company to Host Conference Call Today at 9 a.m. EST CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) --  F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announced third quarter 2021 financial results and a corporate update. Eliot Forster, CEO of F-star Therapeutics, Inc., said, "A year on from listing on NASDAQ, we have delivered on our planned milestones, and through them value for patients, partners and our investors. Our agile, tenacious approach, working with world-leading investigators, continues to

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that the Company will hold a conference call and webcast on November 10, 2021, at 9:00 a.m. EST to review third quarter 2021 financial results and provide a corporate update. To access the call, participants may join via a live webcast on the Investors & News section of the F-star Therapeutics website, under Events and Presentations. To join by phone, participants may dial the following numbers at least

Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company's Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial executive with decades of experience working with and advising private and public life sciences companies. Shaun Chilton, Chairman of the Board of Avacta, commented: "Avacta is at a pivotal time in its e

Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur

invoX Pharma Limited ("invoX"), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited ("Sino Biopharm") (HKEX 1177 HK) with an advancing pipeline of innovative products, today announces that it has successfully completed the acquisition of F-star Therapeutics, Inc. ("F-star") (NASDAQ:FSTX), a clinical-stage biopharmaceutical company pioneering bispecific antibodies in immunotherapy, for an aggregate cash consideration of approximately $161 million (or $7.12 per share). F-star is currently executing Phase 2 trials in Europe and the U.S. in patients with PD-1 acquired resistant head and neck cancer, and in checkpoint inhibitor-naïve patients with non-small cell lung cancer (

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX) ("F-star" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to transform the lives of patients with cancer, today announced that the Committee on Foreign Investment in the United States ("CFIUS") has cleared the previously announced all-cash acquisition of the Company by invoX Pharma Limited ("invoX"). The CFIUS clearance satisfies the Foreign Investment Condition of the ongoing tender offer (the "Offer"), and is the final required regulatory approval needed to complete the proposed merger. As descr

LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- invoX Pharma ("invoX"), a wholly owned subsidiary of Sino Biopharmaceutical Limited ("Sino Biopharm") (HKEX 1177 HK), and F-star Therapeutics, Inc. ("F-star") (NASDAQ:FSTX), today issued the following statement regarding their pending transaction in response to a media report: The parties continue working together in active discussions with the Committee on Foreign Investment in the United States ("CFIUS") about the terms of a mitigation agreement to address CFIUS's concerns regarding potential national security risks posed by the transaction. The parties are actively negotiating with CFIUS regarding the definitive terms of such mitigation agreeme

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX) ("F-star" or the "Company"), a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can live longer and improved lives, today announced new clinical data from its potentially best-in-class clinical asset FS222, a CD137/PD-L1 targeting tetravalent bispecific antibody, at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) Annual Congress which is being held from December 7 - 9, 2022, in Geneva. FS222 targets critical tumoral immune-suppressing pathways via PD-L1 checkpoint blockade and has exhibited i

- FS118 is Well-Tolerated Across all Dose Levels with No Serious Adverse Events Related to FS118 Therapy - Novel mechanism showing Increased Peripheral Immune Cells and LAG-3 shedding - 54.8% Disease Control Rate in PD-L1 Acquired Resistance Patients at doses > 1mg/kg, including one partial response in Anaplastic Thyroid Cancer - Further studies ongoing in Acquired Resistance Squamous Cell Carcinoma of the Head and Neck and Checkpoint Inhibitor Naïve Non-small cell lung cancer and diffuse B cell lymphoma CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX) ("F-star" or the "Company"), a clinical-stage biopharmaceutic

Previously announced agreement for F-star Therapeutics to be acquired by invoX Pharma; transaction expected to close in the second half of 2022 License Agreement with Takeda to Develop and Commercialize a Novel Next-Generation Immuno-Oncology Bispecific Antibody TherapeuticFS118 Cleared the Futility Hurdle for the Initial Stage of the Head and Neck Acquired Resistance Cancer Trial Initiation of Combination Dosing with FS120 and KEYTRUDA® in Patients with Advanced Cancers under Supply Agreement with MSD Company Will Not be Hosting Q2 2022 Earnings Conference Call Due to the Pending Transaction with invoX Pharma CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE)

invoX Pharma Limited ("invoX"), a wholly owned subsidiary of Sino Biopharmaceutical Limited ("Sino Biopharm") (HKEX 1177 HK), focused on research and development (R&D) and business development activities outside of China, and F-star Therapeutics, Inc. ("F-star") (NASDAQ:FSTX), a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can live longer and improved lives, today announced that invoX has extended the expiration of its previously announced tender offer for all of the issued and outstanding shares of F-star common stock for a price of $7.12 per share. The tender offer is now scheduled to expire at 05:00 p.m., Eastern Time, on Sep

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX) ("F-star"), operating through its subsidiary, F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can live longer and improved lives, today announced that it has entered into a license agreement with Takeda. Under the terms of the agreement, F-star will grant Takeda a worldwide, exclusive royalty-bearing license to research, develop, and commercialize a bispecific antibody against an immuno-oncology target using F-star's proprietary Fcab™ and mAb2 ™ platforms. Takeda will be responsib

H.C. Wainwright downgraded F-star Therapeutics from Buy to Neutral and set a new price target of $7.00 from $35.00 previously

Ladenburg Thalmann resumed coverage of F-star Therapeutics with a rating of Buy and set a new price target of $15.00

SVB Leerink reiterated coverage of F-star Therapeutics with a rating of Outperform and set a new price target of $35.00 from $39.00 previously

SVB Leerink initiated coverage of F-star Therapeutics with a rating of Outperform and set a new price target of $39.00

B. Riley Securities initiated coverage of F-star Therapeutics with a rating of Buy and set a new price target of $28.00

HC Wainwright & Co. initiated coverage of F-star Therapeutics with a rating of Buy and set a new price target of $35.00

Oppenheimer initiated coverage of F-star Therapeutics with a rating of Outperform and set a new price target of $30.00

William Blair initiated coverage of F-star Therapeutics with a rating of Outperform

Laidlaw & Co. initiated coverage of F-star Therapeutics with a rating of Buy and set a new price target of $32.00

HC Wainwright initiated coverage of F-star Therapeutics with a rating of Buy and set a new price target of $35.00

4 - F-star Therapeutics, Inc. (0001566373) (Issuer)

4 - F-star Therapeutics, Inc. (0001566373) (Issuer)

4 - F-star Therapeutics, Inc. (0001566373) (Issuer)

4 - F-star Therapeutics, Inc. (0001566373) (Issuer)

4 - F-star Therapeutics, Inc. (0001566373) (Issuer)

4 - F-star Therapeutics, Inc. (0001566373) (Issuer)

4 - F-star Therapeutics, Inc. (0001566373) (Issuer)

4 - F-star Therapeutics, Inc. (0001566373) (Issuer)

4 - F-star Therapeutics, Inc. (0001566373) (Issuer)

4 - F-star Therapeutics, Inc. (0001566373) (Issuer)

15-12G - F-star Therapeutics, Inc. (0001566373) (Filer)

EFFECT - F-star Therapeutics, Inc. (0001566373) (Filer)

EFFECT - F-star Therapeutics, Inc. (0001566373) (Filer)

EFFECT - F-star Therapeutics, Inc. (0001566373) (Filer)

EFFECT - F-star Therapeutics, Inc. (0001566373) (Filer)

EFFECT - F-star Therapeutics, Inc. (0001566373) (Filer)

S-8 POS - F-star Therapeutics, Inc. (0001566373) (Filer)

S-8 POS - F-star Therapeutics, Inc. (0001566373) (Filer)

S-8 POS - F-star Therapeutics, Inc. (0001566373) (Filer)

S-8 POS - F-star Therapeutics, Inc. (0001566373) (Filer)